Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 65
Filter
1.
J Immunol Methods ; 499: 113148, 2021 12.
Article in English | MEDLINE | ID: mdl-34560073

ABSTRACT

Using a recombinant protein antigen for antibody testing shows a sum of antibody responses to multiple different immune epitopes existing in the protein antigen. In contrast, the antibody testing to an immunogenic peptide epitope reflects a singular antibody response to the individual peptide epitope. Therefore, using a panel of peptide epitopes provides an advantage for profiling multiple singular antibody responses with potential to estimate recent malaria exposure in human infections. However, transitioning from malaria immune epitope peptide-based ELISA to an all peptide bead-based multiplex Luminex assay presents some challenges including variation in the ability of different peptides to bind beads. The aim of this study was to develop a peptide coupling method while demonstrating the utility of these peptide epitopes from multiple stage antigens of Plasmodium falciparum for measuring antibodies. Successful coupling of peptide epitopes to beads followed three steps: 1) development of a peptide tag appended to the C-terminus of each peptide epitope consisting of beta-alanine-lysine (x 4)--cysteine, 2) bead modification with a high concentration of adipic acid dihydrazide, and 3) use of the peptide epitope as a blocker in place of the traditional choice, bovine serum albumin (BSA). This new method was used to couple 12 peptide epitopes from multiple stage specific antigens of P. falciparum, 1 Anopheles mosquito salivary gland peptide, and 1 Epstein-Barr virus peptide as an assay control. The new method was applied to testing of IgG in pooled samples from 30 individuals with previously repeated malaria exposure in western Kenya and IgM and IgG in samples from 37 U.S. travelers with recent exposure to malaria. The new peptide-bead coupling method and subsequent multiplex Luminex assay showed reliable detection of IgG to all 14 peptides in Kenyan samples. Among 37 samples from U.S. travelers recently diagnosed with malaria, IgM and IgG to the peptide epitopes were detected with high sensitivity and variation. Overall, the U.S. travelers had a much lower positivity rates of IgM than IgG to different peptide epitopes, ranging from a high of 62.2% positive for one epitope to a low of only 5.4% positive for another epitope. In contrast, the travelers had IgG positive rates from 97.3% to 91.9% to various peptide epitopes. Based on the different distribution in IgM and IgG positivity to overall number of peptide epitopes and to the number of pre-erythrocytic, erythrocytic, gametocytic, and salivary stage epitopes at the individual level, four distinct patterns of IgM and IgG responses among the 37 samples from US travelers were observed. Independent peptide-bead coupling and antibody level readout between two different instruments also showed comparable results. Overall, this new coupling method resolves the peptide-bead coupling challenge, is reproducible, and can be applied to any other immunogenic peptide epitopes. The resulting all peptide bead-based multiplex Luminex assay can be expanded to include other peptide epitopes of P. falciparum, different malaria species, or other diseases for surveillance, either in US travelers or endemic areas.


Subject(s)
Antibodies/analysis , Enzyme-Linked Immunosorbent Assay , Epitopes/immunology , Peptides/chemistry , Plasmodium falciparum/chemistry , Antibodies/immunology , Humans , Peptides/chemical synthesis , Peptides/immunology , Plasmodium falciparum/immunology
2.
Br J Nutr ; 123(5): 516-528, 2020 03 14.
Article in English | MEDLINE | ID: mdl-31771683

ABSTRACT

Glucose intolerance during pregnancy - a major driver of gestational diabetes mellitus (GDM) - has significant short- and long-term health consequences for both the mother and child. As GDM prevalence continues to escalate, there is growing need for preventative strategies. There is limited but suggestive evidence that myo-inositol (MI) and probiotics (PB) could improve glucose tolerance during pregnancy. The present study tested the hypothesis that MI and/or PB supplementation would reduce the risk of glucose intolerance during pregnancy. Female C57BL/6 mice were randomised to receive either no treatment, MI, PB (Lactobacillus rhamnosus and Bifidobacterium lactis) or both (MIPB) for 5 weeks. They were then provided with a high-fat diet for 1 week before mating commenced and throughout mating/gestation, while remaining on their respective treatments. An oral glucose tolerance test occurred at gestational day (GD) 16·5 and tissue collection at GD 18·5. Neither MI nor PB, separately or combined, improved glucose tolerance. However, MI and PB both independently increased adipose tissue expression of Ir, Irs1, Akt2 and Pck1, and PB also increased Pparγ. MI was associated with reduced gestational weight gain, whilst PB was associated with increased maternal fasting glucose, total cholesterol and pancreas weight. These results suggest that MI and PB may improve insulin intracellular signalling in adipose tissue but this did not translate to meaningful differences in glucose tolerance. The absence of fasting hyperglycaemia or insulin resistance suggests this is a very mild model of GDM, which may have affected our ability to assess the impact of these nutrients.


Subject(s)
Dietary Supplements , Glucose Intolerance/therapy , Inositol/administration & dosage , Pregnancy Complications/therapy , Probiotics/therapeutic use , Adipose Tissue/metabolism , Animals , Blood Glucose/metabolism , Diabetes, Gestational/etiology , Diabetes, Gestational/prevention & control , Diet, High-Fat , Disease Models, Animal , Female , Glucose Intolerance/blood , Glucose Tolerance Test , Insulin/blood , Insulin Resistance , Mice , Mice, Inbred C57BL , Pregnancy , Pregnancy Complications/blood
3.
Diabetes Obes Metab ; 18(5): 533-6, 2016 May.
Article in English | MEDLINE | ID: mdl-26847401

ABSTRACT

Therapeutic administration of peptides may result in anti-drug antibody (ADA) formation, hypersensitivity adverse events (AEs) and reduced efficacy. As a large peptide, the immunogenicity of once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist dulaglutide is of considerable interest. The present study assessed the incidence of treatment-emergent dulaglutide ADAs, hypersensitivity AEs, injection site reactions (ISRs), and glycaemic control in ADA-positive patients in nine phase II and phase III trials (dulaglutide, N = 4006; exenatide, N = 276; non-GLP-1 comparators, N = 1141). Treatment-emergent dulaglutide ADAs were detected using a solid-phase extraction acid dissociation binding assay. Neutralizing ADAs were detected using a cell-based assay derived from human endothelial kidney cells (HEK293). A total of 64 dulaglutide-treated patients (1.6% of the population) tested ADA-positive versus eight (0.7%) from the non-GLP-1 comparator group. Of these 64 patients, 34 (0.9%) had dulaglutide-neutralizing ADAs, 36 (0.9%) had native-sequence GLP-1 (nsGLP-1) cross-reactive ADAs and four (0.1%) had nsGLP-1 neutralization ADAs. The incidence of hypersensitivity AEs and ISRs was similar in the dulaglutide versus placebo groups. No dulaglutide ADA-positive patient reported hypersensitivity AEs. Because of the low incidence of ADAs, it was not possible to establish their effect on glycaemic control.


Subject(s)
Antibodies, Neutralizing/analysis , Diabetes Mellitus, Type 2/complications , Drug Hypersensitivity/complications , Drugs, Investigational/adverse effects , Glucagon-Like Peptide-1 Receptor/agonists , Glucagon-Like Peptides/analogs & derivatives , Hypoglycemic Agents/adverse effects , Immunoglobulin Fc Fragments/adverse effects , Recombinant Fusion Proteins/adverse effects , Antibodies, Neutralizing/isolation & purification , Cross Reactions , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/drug therapy , Diabetes Mellitus, Type 2/immunology , Dose-Response Relationship, Drug , Drug Administration Schedule , Drug Eruptions/complications , Drug Eruptions/epidemiology , Drug Eruptions/physiopathology , Drug Hypersensitivity/epidemiology , Drug Hypersensitivity/physiopathology , Drugs, Investigational/administration & dosage , Drugs, Investigational/therapeutic use , Glucagon-Like Peptide-1 Receptor/antagonists & inhibitors , Glucagon-Like Peptide-1 Receptor/metabolism , Glucagon-Like Peptides/administration & dosage , Glucagon-Like Peptides/adverse effects , Glucagon-Like Peptides/therapeutic use , Humans , Hyperglycemia/chemically induced , Hyperglycemia/prevention & control , Hypoglycemia/prevention & control , Hypoglycemic Agents/administration & dosage , Hypoglycemic Agents/therapeutic use , Immunoglobulin Fc Fragments/administration & dosage , Immunoglobulin Fc Fragments/therapeutic use , Incidence , Injections, Subcutaneous , Middle Aged , Recombinant Fusion Proteins/administration & dosage , Recombinant Fusion Proteins/therapeutic use , Risk , Severity of Illness Index , Solid Phase Extraction
4.
Diabetes Obes Metab ; 16(4): 344-50, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24118909

ABSTRACT

AIMS: To assess the pharmacokinetics (PK) and glucodynamics (GD) of LY2605541 in patients with type 2 diabetes mellitus. METHODS: This parallel-group, open-label, dose-escalation study examined the PK and GD of basal insulin LY2605541 after single and multiple-dose administration. Fixed doses of LY2605541 (0.33-1.00 U/kg) were given once-daily (QD) for 14 days to insulin-treated patients with type 2 diabetes. A 24-h euglycaemic glucose clamp was conducted on days 1 and 14. RESULTS: PK steady state was achieved within 7-10 days and the peak-to-trough fluctuation was <2, translating to a nearly 'peakless' glucose infusion rate at steady state and with a duration of action of at least 24 h. Across dose levels t1/2 ranged from 44.7 to 75.5 h (~2-3 days). As steady state was achieved, there were dose-dependent reductions in the prandial insulin dose and in fasting blood glucose, which decreased to 60-100 mg/dl across dose levels. Within-patient variability was <14 and <26% for the area under the concentration versus time curve (AUC) of the 8-point blood glucose profile and fasting blood glucose, respectively. The nocturnal glucose control between 03:00 and 09:00 hours was relatively unchanged. Mild hypoglycaemia was the most common adverse event. CONCLUSIONS: In this Phase I study of fixed LY2605541 doses without titration, LY2605541 was well-tolerated and demonstrated a flat PK and GD profile accompanied by glucose normalization, prandial insulin dose reduction and no severe hypoglycaemia.


Subject(s)
Blood Glucose/drug effects , C-Peptide/drug effects , Diabetes Mellitus, Type 2/drug therapy , Glycated Hemoglobin/drug effects , Hypoglycemic Agents/pharmacokinetics , Insulin Lispro/pharmacokinetics , Polyethylene Glycols/pharmacokinetics , Adolescent , Adult , Aged , Area Under Curve , Blood Glucose/metabolism , C-Peptide/metabolism , Diabetes Mellitus, Type 2/metabolism , Drug Administration Schedule , Female , Glucose Clamp Technique , Glycated Hemoglobin/metabolism , Humans , Hypoglycemia/chemically induced , Hypoglycemic Agents/administration & dosage , Insulin Lispro/administration & dosage , Male , Middle Aged , Polyethylene Glycols/administration & dosage , Treatment Outcome
5.
Acta Physiol (Oxf) ; 210(1): 161-73, 2014 Jan.
Article in English | MEDLINE | ID: mdl-23834457

ABSTRACT

AIM: To investigate the effect of a nutritional mixture (bovine milk oligosaccharides, Lactobacillus rhamnosus NCC4007, arachidonic and docosahexaenoic acid) on growth of intrauterine growth-restricted (IUGR) rats. METHODS: IUGR was induced by maternal food restriction. The offspring (males and females) were assigned to: REF (non-IUGR, no mixture), IUGRc (IUGR, no mixture), or IUGRmx (IUGR, mixture). The mixture was given from day 7 to day 58, when tissues and plasma from half of the animals were collected for hormones, metabolites and microarray analysis. The rest received a high-fat diet (HFD) until day 100. Glucose tolerance was measured at 56 and 98 days, and body fat content at 21, 52 and 97 days. RESULTS: IUGRmx had the greatest growth during lactation, but from day 22 to day 54, both IUGR groups gained less body weight than the REF (P < 0.05). In the short-term (58 days), IUGRmx tended to be longer (P = 0.06) and had less body fat (P = 0.03) than IUGRc. These differences were not seen after HFD. Microarray analysis of hepatic mRNA expression at 58 and 100 days revealed a gender-dependent treatment effect, and expression of genes related to lipid metabolism was the most affected. Twelve of these genes were selected for studying differences in DNA methylation in the promoter region, for some, we observed age- and gender-related differences but none because of treatment. CONCLUSION: The nutritional intervention promoted catch-up growth and normalized excessive adiposity in IUGR animals at short-term. The benefits did not extend after a period of HFD. IUGR and early diet had gender-dependent effects on hepatic gene expression.


Subject(s)
Adiposity/drug effects , Body Size , Fatty Acids, Unsaturated/therapeutic use , Fetal Growth Retardation/physiopathology , Fetal Growth Retardation/therapy , Lacticaseibacillus rhamnosus , Milk/chemistry , Weight Gain/drug effects , Animals , Female , Male , Rats , Rats, Sprague-Dawley
6.
Diabetes Obes Metab ; 14(6): 546-54, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22236356

ABSTRACT

AIMS: Antibody formation to therapeutic peptides is common. This analysis characterizes the time-course and cross-reactivity of anti-exenatide antibodies and potential effects on efficacy and safety. METHODS: Data from intent-to-treat patients in 12 controlled (n = 2225,12-52 weeks) and 5 uncontrolled (n = 1538, up to 3 years) exenatide twice-daily (BID) trials and 4 controlled (n = 653,24-30 weeks) exenatide once weekly (QW) trials with 1 uncontrolled period (n = 128,52 weeks) were analysed. RESULTS: Mean titres peaked early (6-22 weeks) and subsequently declined. At 30 weeks, 36.7% of exenatide BID patients were antibody-positive; 31.7% exhibited low titres (≤125) and 5.0% had higher titres (≥625). Antibody incidence declined to 16.9% (1.4% higher titre) at 3 years. Similarly, 56.8% of exenatide QW patients were antibody-positive (45.0% low/11.8% higher titre) at 24-30 weeks, declining to 45.4% positive (9.2% higher titre) at 52 weeks. Treatment-emergent anti-exenatide antibodies from a subset of patients tested did not cross-react with human GLP-1 or glucagon. Other than injection-site reactions, adverse event rates in antibody-positive and antibody-negative patients were similar. Efficacy was robust in both antibody-negative and antibody-positive patients (mean HbA1c change: -1.0 and -0.9%, respectively, exenatide BID; -1.6% and -1.3% exenatide QW). No correlation between change in HbA1c and titre was observed for exenatide BID, although mean reductions were attenuated in the small subset of patients (5%) with higher titres. A significant correlation was observed for exenatide QW with no difference between antibody-negative and low-titre patients, but an attenuated mean reduction in the subset of patients (12%) with higher titres. CONCLUSIONS: Low-titre anti-exenatide antibodies were common with exenatide treatment (32% exenatide BID, 45% exenatide QW patients), but had no apparent effect on efficacy. Higher-titre antibodies were less common (5% exenatide BID, 12% exenatide QW) and within that titre group, increasing antibody titre was associated with reduced average efficacy that was statistically significant for exenatide QW. Other than injection-site reactions, anti-exenatide antibodies did not impact the safety of exenatide.


Subject(s)
Antibodies, Anti-Idiotypic/immunology , Blood Glucose/metabolism , Diabetes Mellitus, Type 2/immunology , Glucagon/pharmacology , Hypoglycemic Agents/immunology , Peptides/immunology , Venoms/immunology , Adult , Aged , Antibodies, Anti-Idiotypic/adverse effects , Blood Glucose/drug effects , Blood Glucose/immunology , Cross Reactions/drug effects , Cross Reactions/immunology , Diabetes Mellitus, Type 2/drug therapy , Enzyme-Linked Immunosorbent Assay , Exenatide , Female , Humans , Hypoglycemic Agents/administration & dosage , Male , Middle Aged , Peptides/administration & dosage , Time Factors , Treatment Outcome , Venoms/administration & dosage
7.
Diabetes Obes Metab ; 12(12): 1120-6, 2010 Dec.
Article in English | MEDLINE | ID: mdl-20977585

ABSTRACT

AIM: To investigate the impact of chronic ingestion of sebacic acid (SA), a 10-carbon medium-chain dicarboxylic acid, on glycaemic control in a mouse model of type 2 diabetes (T2D). METHODS: Three groups of 15 db/db mice were fed for 6 weeks either a chow diet (Ctrl) or a chow diet supplemented with 1.5 or 15% (SA(1.5%) and SA(15%) , respectively) energy from SA. Fasting glycaemia was measured once a week and HbA1c before and after supplementation. An oral glucose tolerance test (OGTT) was performed at the end of the supplementation. Gene expression was determined by transcriptomic analysis on the liver of the Ctrl and SA(15%) groups. RESULTS: After 42 days of supplementation, fasting glycaemia and HbA1c were ∼70 and 25% lower in the SA(15%) group compared with the other groups showing a beneficial effect of SA on hyperglycaemia. During OGTT, plasma glucose area under the curve was reduced after SA(15%) compared with the other groups. This effect was associated with a tendency for an improved insulin response. In the liver, Pck1 and FBP mRNA were statistically decreased in the SA(15%) compared with Ctrl suggesting a reduced hepatic glucose output induced by SA. CONCLUSION: Dietary supplementation of SA largely improves glycaemic control in a mouse model of T2D. This beneficial effect may be due to (i) an improved glucose-induced insulin secretion and (ii) a reduced hepatic glucose output.


Subject(s)
Blood Glucose/metabolism , Decanoic Acids/pharmacology , Diabetes Mellitus, Type 2/metabolism , Dicarboxylic Acids/pharmacology , Glycated Hemoglobin/metabolism , Animals , Blood Glucose/drug effects , Diabetes Mellitus, Type 2/drug therapy , Disease Models, Animal , Fasting , Male , Mice
8.
Int J Clin Pharmacol Ther ; 47(11): 651-8, 2009 Nov.
Article in English | MEDLINE | ID: mdl-19840529

ABSTRACT

OBJECTIVES: This study evaluated the potential effect of exenatide on the pharmacokinetics and pharmacodynamics of lisinopril in patients with mild-to-moderate hypertension. METHODS: 22 patients with mild-to-moderate primary hypertension participated in a double-blind, randomized, placebo-controlled, 2-period, 2-sequence crossover study. Patients on stable lisinopril therapy were randomly assigned to receive subcutaneous exenatide (10 microg b.i.d.) and placebo b.i.d. separated by at least 2 days washout period. The primary pharmacodynamic parameters were baseline-adjusted 24-hour mean systolic and diastolic blood pressure. Steady state plasma lisinopril concentration-time profiles were also assessed. RESULTS: Mean blood pressure changes were not significantly different between exenatide and placebo coadministered with lisinopril. The least squares mean differences (95% CI) between treatments were +1.38 mmHg (-1.41, 4.17) for diastolic and +1.38 mmHg (-1.95, 4.71) for systolic blood pressure. Exenatide delayed the time to attain maximum lisinopril concentration (tmax,ss) by 2 hours but did not significantly alter maximum lisinopril concentration (Cmax,ss) or area under the concentration-time profile (AUCtau,ss) over the 24-hour steady-state dosing interval. CONCLUSIONS: This study demonstrated that concurrent administration of exenatide did not produce clinically relevant changes in blood pressure and did not significantly alter lisinopril pharmacokinetics in patients with mild-to-moderate hypertension.


Subject(s)
Antihypertensive Agents/pharmacology , Hypoglycemic Agents/pharmacology , Lisinopril/pharmacology , Peptides/pharmacology , Venoms/pharmacology , Aged , Antihypertensive Agents/pharmacokinetics , Area Under Curve , Blood Pressure/drug effects , Cross-Over Studies , Double-Blind Method , Drug Interactions , Exenatide , Female , Humans , Hypertension/drug therapy , Injections, Subcutaneous , Least-Squares Analysis , Lisinopril/pharmacokinetics , Male , Middle Aged
9.
Int J Clin Pharmacol Ther ; 46(9): 459-65, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18793576

ABSTRACT

OBJECTIVES: Exenatide is an adjunctive treatment for Type 2 diabetes. This was the first study to evaluate the pharmacokinetics, safety and tolerability of therapeutic doses (5 microg and 10 microg) of exenatide after single and multiple subcutaneous injections in healthy adult Chinese subjects. METHODS: 24 healthy volunteers were randomized to receive either 5 microg or 10 microg of exenatide by subcutaneous injection. Subjects received a single injection of exenatide on Day 1, twice daily on Days 2 and 3, and once on Day 4. Serial blood samples were drawn for pharmacokinetic assessment at pre-dose and up to 12 h post dose on Day 1 and Day 4. Adverse events, vital signs, 12-lead ECG, body weight and clinical laboratory evaluations were assessed. RESULTS: Exenatide, 5 microg and 10 microg, was rapidly absorbed with a median tmax of 1 h after single and multiple doses. Exenatide Cmax and AUCtau,ss were (geometric mean (90% CI)) 145 (119 - 176) pg/ml and 370 (297 - 460) pg x h/ml, respectively, after multiple dosing with 5 microg. The Cmax and AUCtau,ss were 311 (271 - 357) pg/ml and 878 (785 - 983) pg x h/ml, respectively, for 10 microg. Mean half-life (t1/2, range 0.99 - 1.25 h), apparent volume of distribution (Vz/F, 19.2 - 22.3 l), and apparent clearance (CL/F, range 11.4 - 13.5 l/h) remained consistent between single and multiple doses and across the two dose levels. Both the accumulation ratios and linearity index approached 1.0. The most common adverse events were gastrointestinal in nature and mild in severity. The frequency of adverse events increased with dose, such that 8% of subjects who received 5 microg and 42% of subjects who received 10 microg experienced adverse events. CONCLUSIONS: Exenatide was rapidly absorbed, with similar pharmacokinetic properties following single and multiple doses. Exenatide exposure after multiple doses approximately doubled from 5 microg to 10 microg.


Subject(s)
Hypoglycemic Agents/pharmacokinetics , Peptides/pharmacokinetics , Venoms/pharmacokinetics , Adult , Area Under Curve , Asian People , China , Diabetes Mellitus, Type 2/drug therapy , Dose-Response Relationship, Drug , Exenatide , Female , Half-Life , Humans , Hypoglycemic Agents/administration & dosage , Hypoglycemic Agents/adverse effects , Injections, Subcutaneous , Male , Peptides/administration & dosage , Peptides/adverse effects , Tissue Distribution , Venoms/administration & dosage , Venoms/adverse effects
10.
Int J Obes (Lond) ; 32(4): 648-57, 2008 Apr.
Article in English | MEDLINE | ID: mdl-18087263

ABSTRACT

OBJECTIVE: To evaluate the ontogeny of adipose tissue dynamics in obese and lean Zucker rat pups, from suckling to puberty. METHODS: The trial had a two-group parallel design. Sixty-two male Zucker rat pups shared within 15 litters received deuterated water for 5 days, prior killing at different age. Adipose tissues were collected for (2)H-enrichment analyses using mass spectrometry to determine fat cell proliferation and lipid synthesis rates. Rats were assigned to obese and lean rat groups by genotyping. RESULTS: The time course (from days 13 to 55) of all adipose tissue growth showed that the highest fractional rates of fat cell proliferation, triacylglycerol (TG) synthesis and de novo lipogenesis (DNL) took place during early suckling in all rat pups. The appearance of excessive fat mass growth in the obese rats, as compared with lean rats, was first shown through a significant increase in DNL at the end of suckling (P<0.05). The TG synthesis rate was enhanced (P<0.05) from the end of suckling and early postweaning until day 55 (from 122+/-10 to 498+/-78 in obese pups and from 25+/-6 to 75+/-26 mg new TG per day in lean pups (median+/-s.e.m., P<0.01)). In contrast, only by day 55 did the fractional proliferation rate of fat cells in retroperitoneal and epididymal depots in the obese rats supersede that of the lean rats (P<0.05). CONCLUSION: The early suckling period constitutes the most active period for adipose tissue development in normal rats. In the obese Zucker rat model, adipose hypertrophy primarily contributes to the early onset of obesity, while hyperplasia increases after puberty. Early onset of adipose tissue growth may play a determinant role in the development of obesity later in life.


Subject(s)
Adipogenesis , Obesity/physiopathology , Thinness/physiopathology , Adipose Tissue/pathology , Animals , Biomarkers/blood , Body Weight , Cell Proliferation , Lactation/physiology , Lipogenesis , Liver/pathology , Male , Obesity/metabolism , Obesity/pathology , Organ Size , Rats , Rats, Zucker , Thinness/metabolism , Thinness/pathology , Triglycerides/biosynthesis
11.
Int J Obes (Lond) ; 32(1): 112-20, 2008 Jan.
Article in English | MEDLINE | ID: mdl-17637700

ABSTRACT

OBJECTIVE: The objective of this study was to determine the contribution of mesothelial cells, present in human omental adipose tissue (OAT) but not in the subcutaneous depot (SAT), on the expression of inflammation-related factors. DESIGN: Comparison of the expression profiles of inflammation-related genes in mesothelial cells with those in the adipocyte-enriched (AEF) and stromal vascular fractions (SVF) and localization of interleukin-18 (IL-18) expression in adipose depots. SUBJECTS: Eleven obese Caucasian female subjects undergoing gastric bypass surgery (body mass index: 43.6+/-1.3 kg/m(2); age: 41.6+/-2.3 years). MEASUREMENTS: The expression profiles of cytokine and chemokine-related genes in mesothelial cells and in cell fractions prepared from OAT were assessed by the microarray technique. The differential expression of IL-18 was confirmed by real-time PCR and the protein was localized in adipose depots by immunohistochemistry. RESULTS: Microarray data analysis demonstrated that, of the 16 cytokine and chemokine-related genes that were upregulated in mesothelial cells compared with the AEF, IL-18 was the cytokine with the highest differential expression. IL-18 expression was similar in mesothelial cells and the SVF. In both SAT and OAT, IL-18 was immunolocalized in neutrophils and mast cells, but not in macrophages nor adipocytes. This cytokine was also detected in mesothelial cells in OAT. This additional source of expression may explain the higher IL-18 expression levels in OAT than SAT (+5.9-fold). CONCLUSION: By their capacity to express inflammatory-related factors, and in particular the proinflammatory cytokine IL-18 in OAT, mesothelial cells appear as a new player in the process of low-grade inflammation associated with obesity.


Subject(s)
Adipose Tissue/metabolism , Epithelial Cells/metabolism , Interleukin-18/metabolism , Obesity/metabolism , Omentum/metabolism , Subcutaneous Fat, Abdominal/metabolism , Adipose Tissue/cytology , Adult , Epithelium/metabolism , Female , Humans , Immunohistochemistry , Inflammation/genetics , Interleukin-18/genetics , Microarray Analysis , Obesity/genetics , Reverse Transcriptase Polymerase Chain Reaction
12.
Int J Clin Pharmacol Ther ; 45(2): 114-20, 2007 Feb.
Article in English | MEDLINE | ID: mdl-17323791

ABSTRACT

OBJECTIVE: Exenatide is an adjunctive treatment for type 2 diabetes. Many patients with type 2 diabetes have dyslipidemia, which requires treatment with three hydroxy-3-methyl glutaryl coenzyme (HMG-CoA) reductase inhibitors (statins), hence, concurrent use of exenatide and statins is likely. Exenatide slows gastric emptying, which may alter the absorption rate of co-administered oral medications. Thus, the potential interaction between exenatide and statins was evaluated in two study settings. METHODS: In an open-label, fixed-sequence, clinical pharmacology study, the plasma pharmacokinetics of lovastatin (40 mg after breakfast) in the presence and absence of exenatide (10 microg before breakfast and dinner) was evaluated in 21 healthy subjects. In a second clinical setting, changes in lipid profiles and statin dosage over 30 weeks in patients with type 2 diabetes were retrospectively compared (n = 180 exenatide 10 microg twice daily (BID), n = 168 placebo BID) in a combined analysis of three placebo-controlled, randomized exenatide Phase 3 trials. RESULTS: In healthy subjects, exenatide decreased mean lovastatin area under the plasma concentration time curve from zero to infinity (AUC0-infinity) and maximum plasma concentration (Cmax) by 40 and 28%, respectively, and increased median time to maximum plasma concentration (tmax) by 4 hours. In the exenatide Phase 3 trials, 30-week changes from baseline for low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), total cholesterol, triglycerides and statin dosage were not significantly different between the exenatide and placebo groups treated with statins. CONCLUSIONS: Despite observed changes in lovastatin bioavailability in the pharmacokinetic drug interaction study, exenatide did not negatively affect long-term lipid profiles or statin dosage in patients with concurrent statin therapy. Thus, co-administration of exenatide does not require adjustment in statin dosage.


Subject(s)
Diabetes Mellitus, Type 2/drug therapy , Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacokinetics , Hypoglycemic Agents/pharmacology , Lipids/blood , Lovastatin/pharmacokinetics , Peptides/pharmacology , Venoms/pharmacology , Adolescent , Adult , Aged , Cross-Over Studies , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/metabolism , Drug Interactions , Exenatide , Female , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/blood , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Hypoglycemic Agents/therapeutic use , Lovastatin/blood , Lovastatin/therapeutic use , Male , Middle Aged , Peptides/therapeutic use , Venoms/therapeutic use
13.
Int J Obes (Lond) ; 30 Suppl 4: S50-7, 2006 Dec.
Article in English | MEDLINE | ID: mdl-17133236

ABSTRACT

BACKGROUND: The growing prevalence of childhood overweight and obesity has renewed interest in determining the influence of the maternal and infant diet on the risk of developing excess fat mass later in life. APPROACH: Review of available human and animal data reporting the effects of dietary fat and fat types early in life on adipose development. RESULTS: Rodent studies tend to show that maternal high-fat feeding during pregnancy and lactation results in increased adiposity of the offspring. Nevertheless, today there is a lack of population-based studies investigating this potential detrimental effect of maternal high-fat intake. Most epidemiological studies, performed so far, do not find any association between the level of dietary fat intake of infants and children and body weight and/or fatness. Regarding fat types exposure to high levels of dietary n-6 fatty acids during gestation and post-natal life, has been shown to promote obesity in mice. Nevertheless, other rodent studies do not demonstrate such an effect. CONCLUSION: There is no evidence supporting a restriction of fat intake during the first two post-natal years but the potential detrimental effects of maternal high-fat intake during gestation should be further investigated. The role of dietary fat types as early determinants of childhood obesity has so far been poorly studied. Robust evidence to support the adipogenic effects of n-6 fatty acids enriched-diets is currently lacking but this hypothesis is of importance and should be further evaluated in different animal models as well as in longitudinal human studies.


Subject(s)
Adiposity/physiology , Dietary Fats/administration & dosage , Feeding Behavior/physiology , Obesity/etiology , Animals , Body Weight , Dietary Fats/adverse effects , Dietary Fats/metabolism , Female , Humans , Male , Mice , Obesity/metabolism , Pregnancy , Rats
14.
Lipids Health Dis ; 3: 2, 2004 Feb 18.
Article in English | MEDLINE | ID: mdl-14969592

ABSTRACT

INTRODUCTION: There has been renewed interest in mushroom medicinal properties. We studied cholesterol lowering properties of Ganoderma lucidum (Gl), a renowned medicinal species. RESULTS: Organic fractions containing oxygenated lanosterol derivatives inhibited cholesterol synthesis in T9A4 hepatocytes. In hamsters, 5% Gl did not effect LDL; but decreased total cholesterol (TC) 9.8%, and HDL 11.2%. Gl (2.5 and 5%) had effects on several fecal neutral sterols and bile acids. Both Gl doses reduced hepatic microsomal ex-vivo HMG-CoA reductase activity. In minipigs, 2.5 Gl decreased TC, LDL- and HDL cholesterol 20, 27, and 18%, respectively (P < 0.05); increased fecal cholestanol and coprostanol; and decreased cholate. CONCLUSIONS: Overall, Gl has potential to reduce LDL cholesterol in vivo through various mechanisms. Next steps are to: fully characterize bioactive components in lipid soluble/insoluble fractions; evaluate bioactivity of isolated fractions; and examine human cholesterol lowering properties. Innovative new cholesterol-lowering foods and medicines containing Gl are envisioned.

15.
Cell Death Differ ; 10(9): 1025-31, 2003 Sep.
Article in English | MEDLINE | ID: mdl-12934077

ABSTRACT

Overexpression of SV40 T-antigen (SV40 T-Ag) has been widely used to overcome replicative senescence of human primary cells and to promote cell immortalization. However, in the case of certain cell types, such as preadipocytes, the differentiation process of immortalized cells is blocked by SV40 T-Ag expression. In this study, human telomerase reverse transcriptase (hTERT) and papillomavirus E7 oncoprotein (HPV-E7) genes were coexpressed in human preadipocytes to test whether this combination could maintain cell differentiation capacity after immortalization. We demonstrated that the HPV-E7/hTERT expressing preadipocytes displayed an indefinite life span. Interestingly, immortalized cells were diploid and presented no chromosomic alterations. These immortalized cells were able to accumulate and hydrolyze intracellular triglycerides and to express adipocyte markers. These data demonstrate, for the first time, that coexpression of hTERT and HPV-E7 in human preadipocytes allows cells not only to display an indefinite life span but also to retain their capacity to differentiate.


Subject(s)
Adipocytes/cytology , Cell Transformation, Viral , Oncogene Proteins, Viral/metabolism , Stem Cells/cytology , Telomerase/metabolism , Adipocytes/metabolism , Adult , Cell Differentiation , Cell Line, Transformed , Cells, Cultured , DNA-Binding Proteins , Female , Gene Expression , Humans , Karyotyping , Oncogene Proteins, Viral/genetics , Papillomavirus E7 Proteins , Stem Cells/enzymology , Stem Cells/virology
16.
Placenta ; 24(7): 727-38, 2003 Aug.
Article in English | MEDLINE | ID: mdl-12852863

ABSTRACT

ReoPro (Abciximab), a Fab fragment of a human-murine chimeric monoclonal antibody, binds to glycoprotein IIb/IIIa receptors on human platelets and inhibits platelet aggregation. Can ReoPro transit the human placenta since it does not have an Fc (domain) as does IgG? This question was addressed using an in vitro term human placental lobular dual perfusion model. ReoPro, along with 3H(2)O, inulin or 125I-F105 human IgG(1), were added to the maternal reservoir for 6 or >12 h, ReoPro was equivalent to, or exceeded, clinically relevant plasma concentrations (0.3-3 microg/ml). 3H(2)O rapidly appeared in the fetal circuit, while fetal 14C-inulin never equilibrated with the maternal inulin. After 6 h, 125I-F105 was present with fetal/maternal percentages-0.55 per cent. ReoPro was not detectable (<3.9 ng/ml) in the fetal circuit during or at the end of any perfusion. Using immunohistochemistry, ReoPro was only detected attached to maternal and fetal platelets, and to the trophoblastic surface of the placental villi. Only pharmaceutically insignificant amounts of ReoPro were detected in the fetal circuit, which demonstrates a barrier capacity of the human term placenta for this Fab fragment compared with IgG.


Subject(s)
Antibodies, Monoclonal/pharmacokinetics , Immunoglobulin Fab Fragments , Immunoglobulin G/metabolism , Maternal-Fetal Exchange , Placenta/metabolism , Abciximab , Adult , Biological Transport , Blood Platelets/metabolism , Chorionic Villi/metabolism , Female , Fetal Blood/metabolism , Humans , Immunoenzyme Techniques , Inulin/pharmacokinetics , Iodine Radioisotopes , Organ Culture Techniques , Perfusion , Placenta/cytology , Pregnancy , Tritium , Water/metabolism
17.
J Neurosci Res ; 70(1): 46-56, 2002 Oct 01.
Article in English | MEDLINE | ID: mdl-12237863

ABSTRACT

During rat brain development, striatal proteoglycan (PG) expression shows specific spatio-temporal modifications suggesting a possible role in the guidance of its dopaminergic afferents. The effects of individual glycosaminoglycans (GAGs) on dopaminergic (DA) neuronal adhesion and outgrowth were therefore studied. We tested the behavior of dissociated embryonic rat mesencephalic cells cultivated on substrate-bound GAGs. Neuronal attachment was very limited and quantitative morphometry revealed variations in DA fiber outgrowth depending on the type and the concentration of GAG used. Next, we developed a cryoculture system to examine how neurons react toward GAGs expressed in situ. Rat brain slices from different developmental stages were used as substrates for embryonic mesencephalic explants. Preferential regions of adherence and outgrowth were observed: the striatum was found to be the most permissive, whereas the cortex was inhibitory. Western blotting experiments confirmed quantitative and qualitative changes in chondroitin sulfate (neurocan, phosphacan) and keratan sulfate (KS) containing PGs in these substrates and enzymatic digestion of GAGs before cryoculture revealed a substantial involvement of PGs in DA neuron adhesion and outgrowth. In particular, CSPGs seemed to mediate the permissive effect of the striatum, whereas KS confers an inhibitory effect to the cortex. PGs may thus be important for limiting midbrain projections to the striatum during development and for maintaining topography in the adult.


Subject(s)
Chondroitin/physiology , Keratan Sulfate/physiology , Mesencephalon/physiology , Animals , Animals, Newborn , Blotting, Western , Cell Adhesion/drug effects , Cell Adhesion/physiology , Chondroitin/pharmacology , Chondroitin Sulfate Proteoglycans/metabolism , Corpus Striatum/growth & development , Corpus Striatum/metabolism , Corpus Striatum/physiology , Cytological Techniques , Dopamine/physiology , Glycosaminoglycans/pharmacology , Glycosaminoglycans/physiology , Immunohistochemistry , Keratan Sulfate/pharmacology , Laminin/physiology , Lectins, C-Type , Mesencephalon/drug effects , Mesencephalon/growth & development , Nerve Tissue Proteins/metabolism , Neurites/drug effects , Neurites/physiology , Neurocan , Organ Culture Techniques , Peptides/physiology , Rats , Rats, Sprague-Dawley , Receptor-Like Protein Tyrosine Phosphatases, Class 5 , Tyrosine 3-Monooxygenase/metabolism
18.
Endocrinology ; 142(10): 4522-8, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11564718

ABSTRACT

GLP-1 (glucagon-like peptide-1) is a potent insulin secretagogue released from L cells in the intestine. The regulation of GLP-1 secretion has been described both in vivo and in vitro in several animal species, but data from human cellular models are lacking. For this purpose, factors and cell-signaling pathways regulating GLP-1 secretion were investigated in the NCI-H716 human intestinal cell line. After differentiation, these cells homogeneously produced 16.8 pmol GLP-1/mg protein with a basal release of 4.2% during a 2-h incubation period. Nutrients, such as palmitic acid, oleic acid, and meat hydrolysate, stimulated GLP-1 secretion in a dose-dependent manner, as did the cholinergic agonist carbachol and the neuromediator gastrin-releasing peptide. Along with stimulating GLP-1 release, gastrin-releasing peptide, like ionomycin, increased intracellular calcium levels. Activators of PKA and PKC were able to increase GLP-1 secretion in NCI-H716 cells. However, neither PKA activators nor meat hydrolysate increased proglucagon mRNA levels. These findings indicate that the NCI-H716 cell line constitutes a unique model to study the cellular mechanism of GLP-1 secretion in humans and suggest potential interspecies divergence in the regulation of proglucagon gene expression in enteroendocrine cells.


Subject(s)
Glucagon/metabolism , Intestines/physiology , Peptide Fragments/metabolism , Protein Precursors/metabolism , Animals , Cell Line , Diet , Dose-Response Relationship, Drug , Glucagon-Like Peptide 1 , Humans , Oleic Acid/pharmacology , Palmitic Acid/pharmacology , Protein Hydrolysates/pharmacology
19.
FASEB J ; 15(11): 2033-5, 2001 Sep.
Article in English | MEDLINE | ID: mdl-11511517

ABSTRACT

The skeletal muscle mitochondrial uncoupling protein-3 (UCP3) promotes substrate oxidation, but direct evidence for its metabolic role is lacking. Here, we show that UCP3 overexpression in cultured human muscle cells decreased mitochondrial membrane potential (DYm). Despite this, the ATP content was not significantly decreased compared with control cells, whereas ADP content was reduced and thus the ATP/ADP ratio raised. This finding was contrasts with the effect caused by the chemical protonophoric uncoupler, CCCP, which lowered DYm, ATP, and the ATP/ADP ratio. UCP3-overexpression enhanced oxidation of oleate, regardless of the presence of glucose, whereas etomoxir, which blocks fatty acid entry to mitochondria, suppressed the UCP3 effect. Glucose oxidation was stimulated in UCP3-overexpressing cells, but this effect was inhibited by oleate. UCP3 caused weak increase of both 2-Deoxyglucose uptake and glycolytic rate, which differed from the marked stimulation by CCCP. We concluded that UCP3 promoted nutrient oxidation by lowering DYm and enhanced fatty acid-dependent inhibition of glucose oxidation. Unlike the uncoupler CCCP, however, UCP3 raised the ATP/ADP ratio and modestly increased glucose uptake and glycolysis. We propose that this differential effect provides a biological significance to UCP3, which is up-regulated in metabolic stress situations where it could be involved in nutrient partitioning.


Subject(s)
Adenosine Diphosphate/metabolism , Adenosine Triphosphate/metabolism , Carrier Proteins/physiology , Fatty Acids/metabolism , Glucose/metabolism , Intracellular Membranes/physiology , Mitochondria, Muscle/physiology , Carrier Proteins/genetics , Cells, Cultured , Gene Expression , Glycolysis , Humans , Ion Channels , Membrane Potentials/physiology , Mitochondrial Proteins , Muscles/cytology , Muscles/metabolism , Muscles/physiology , Oxidation-Reduction , Uncoupling Agents , Uncoupling Protein 3
20.
Food Chem Toxicol ; 39(6): 549-56, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11346484

ABSTRACT

The coffee-specific diterpenes cafestol and kahweol (C + K) have been reported to be anticarcinogenic in several animal models. Proposed mechanisms involve a co-ordinated modulation of several enzymes responsible for carcinogen detoxification, thus preventing reactive agents interacting with critical target sites. To address the human relevance of the chemoprotective effects of C + K against aflatoxin B(1) (AFB1) genotoxicity observed in rat liver, and to compare the mechanisms of protection involved in both species, animal and human hepatic in vitro test systems were applied. In rat primary hepatocytes, C + K reduced the expression of cytochrome P450 CYP 2C11 and CYP 3A2, the key enzymes responsible for AFB1 activation to the genotoxic metabolite aflatoxin B1-8,9 epoxide (AFBO). In addition, these diterpenes induced significantly GST Yc2, the most efficient rat GST subunit involved in AFBO detoxification. These effects of C + K resulted in a marked dose-dependent inhibition of AFB1-DNA binding in this rat in vitro culture system. Their relevance in humans was addressed using liver epithelial cell lines (THLE) stably transfected to express AFB1 metabolising cytochrome P450s. In these cells, C + K also produced a significant inhibition of AFB1-DNA adducts formation linked with an induction of the human glutathione S-transferase GST-mu. Altogether, these results suggest that C + K may have chemoprotective activity against AFB1 genotoxicity in both rats and humans.


Subject(s)
Aflatoxin B1/toxicity , Coffee/chemistry , Cytochrome P-450 Enzyme System/metabolism , Diterpenes/pharmacology , Liver/drug effects , Animals , Blotting, Western , Cells, Cultured , Chemoprevention , Cytochrome P-450 Enzyme System/genetics , DNA Adducts/drug effects , Dose-Response Relationship, Drug , Gene Expression Regulation, Enzymologic/drug effects , Hepatocytes/drug effects , Hepatocytes/enzymology , Humans , Liver/cytology , Liver/enzymology , Rats , Rats, Sprague-Dawley
SELECTION OF CITATIONS
SEARCH DETAIL
...